Morgan Ebert, Managing Editor

Elective egg freezing increased nearly fourfold from 2014 to 2021, but only 5.7% of women later returned to use their frozen oocytes.

Take a quick look at everything you may have missed in October, including the latest FDA updates, top stories, and exclusive interviews.

Research at The Menopause Society 2025 meeting highlighted safety, education, and individualized care in menopause management.

Earlier menopause accelerates memory decline in women with APOE ε4 or inflammation, highlighting sex-specific Alzheimer disease risk factors.

A systematic review found estrogen-based hormone therapy did not consistently reduce anxiety or depression in midlife women.

A new study finds that earlier menopause and reduced cardiac function may together worsen brain health, highlighting dementia risk factors.

Women with early natural menopause face a 27% higher risk of metabolic syndrome, underscoring the need for early cardiometabolic screening.

A study finds postmenopausal women have higher rates of dry eye disease, emphasizing the need for routine screening in clinical practice.

Real-world data show fezolinetant improves vasomotor symptoms, sleep, and work productivity in postmenopausal women.

Starting estrogen therapy in perimenopause was associated with reduced risks of breast cancer, heart attack, and stroke, study shows.

A new study found that transdermal hormone therapy may lower anxiety and depression risk compared with oral therapy in postmenopausal women.

A Wake Forest study finds that provider specialty and training shape how women receive medication treatment for menopause symptoms.

Most perimenopausal and menopausal women report digestive symptoms, but few receive diagnosis or adequate care, new UK study finds.

Researchers highlight overlap between menopause and TBI symptoms, calling for hormone-informed tools in brain injury assessment.

Tebipenem HBr met primary endpoints in a phase 3 trial, showing oral efficacy comparable to IV carbapenem for complicated urinary tract infections.

A review presented at The Menopause Society 2025 highlights the links between menopause-related brain changes and cognitive function.

A large TriNetX analysis found hormone therapy use in postmenopausal women was linked to a higher incidence of autoimmune diseases.

The Menopause Society’s 2025 meeting heads to Orlando with sessions on longevity, hormones, cognition, and care innovation at midlife and beyond.

Supplemental molecular breast imaging more than doubled invasive cancer detection rates in women with dense breasts.

New SMFM guidance outlines key recommendations for diagnosing, counseling, and managing heart failure in pregnancy and postpartum.

On October 2, 2025, the FDA approved a generic version of mifepristone to be used in a regimen with misoprostol for abortion.

Take a quick look at everything you may have missed during the third quarter of 2025, including the latest FDA approvals, top stories, and exclusive interviews.

Take a quick look at everything you may have missed in September, including the latest FDA updates, top stories, and exclusive interviews.

Check out the top conferences happening in the fourth quarter of 2025.

Mothers with multiple adverse childhood experiences faced double the risk of preterm birth, highlighting intergenerational health effects.

A study of 1.2 million children found no causal link between prenatal opioid use and autism or ADHD.

A national poll finds most women underestimate diet’s role in reducing menopause symptoms, despite evidence for plant-based diets with soy.

The 2025 amendment updates diagnostic, treatment, and prevention strategies for recurrent urinary tract infections in women.

Universal EHR-based decision support eliminated racial disparities in adolescent chlamydia and gonorrhea testing in pediatric EDs.

An international review found rising maternal age, increasing complications, and ongoing disparities in maternity care across 3 nations.